Citius Pharmaceuticals Inc (CTXR)

• $0.52

  $0.57

  $0.53
  

  1.89%

  Downside

  Day's Volatility :8.19%

  Upside

  6.43%

  
• $0.48

  $1.07

  $0.53
  

  9.43%

  Downside

  52 Weeks Volatility :55.14%

  Upside

  50.47%

  

Returns

What analysts predicted

Upside of 781.13%

• Armistice Capital, LLC

  5.62%

• Vanguard Group Inc

  3.50%

• Geode Capital Management, LLC

  1.63%

• State Street Corporation

  1.22%

• BlackRock Inc

  1.00%

• Goldman Sachs Group Inc

  0.66%

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.